Over the years we have documented many of the Sanofi diabetes partnerships that have failed. MannKind and AgaMatrix are two that quickly come to mind but there have been many others including the latest with Lexicon. Now if there is one thing, we have learned other than Sanofi is the worst partner in diabetes and believe us that’s saying something. Sanofi in one respect is an great EX-partner as get a load of this from a Lexicon release;
“Under the terms of the settlement, Sanofi will pay Lexicon $260 million, of which $208 million is payable upfront and . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.